Astria Therapeutics, Inc. (NASDAQ:ATXS) Sees Significant Growth in Short Interest

Astria Therapeutics, Inc. (NASDAQ:ATXS) was the target of a significant increase in short interest in November. As of November 30th, there was short interest totalling 3,150,000 shares, an increase of 8.6% from the November 15th total of 2,900,000 shares. Based on an average trading volume of 321,400 shares, the short-interest ratio is presently 9.8 days. Approximately 6.5% of the company’s stock are sold short.

Astria Therapeutics Trading Down 3.0 %

Shares of NASDAQ ATXS traded down $0.29 during trading hours on Friday, reaching $9.52. The stock had a trading volume of 195,675 shares, compared to its average volume of 593,820. The firm has a 50-day moving average of $10.82 and a 200-day moving average of $10.69. The firm has a market cap of $537.21 million, a price-to-earnings ratio of -4.56 and a beta of 0.67. Astria Therapeutics has a fifty-two week low of $5.80 and a fifty-two week high of $16.90.

Institutional Investors Weigh In On Astria Therapeutics

Several large investors have recently modified their holdings of ATXS. FMR LLC grew its holdings in shares of Astria Therapeutics by 29.2% during the third quarter. FMR LLC now owns 7,822,275 shares of the biotechnology company’s stock worth $86,123,000 after buying an additional 1,767,714 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of Astria Therapeutics by 152.3% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 314,265 shares of the biotechnology company’s stock worth $3,460,000 after acquiring an additional 189,727 shares during the period. Vestal Point Capital LP boosted its holdings in shares of Astria Therapeutics by 23.1% in the third quarter. Vestal Point Capital LP now owns 4,000,000 shares of the biotechnology company’s stock valued at $44,040,000 after acquiring an additional 750,000 shares in the last quarter. Sofinnova Investments Inc. acquired a new position in shares of Astria Therapeutics during the second quarter worth about $552,000. Finally, ClariVest Asset Management LLC purchased a new position in Astria Therapeutics during the second quarter worth about $731,000. 98.98% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have weighed in on ATXS shares. HC Wainwright restated a “buy” rating and set a $16.00 price target on shares of Astria Therapeutics in a report on Tuesday, December 10th. Oppenheimer raised their target price on shares of Astria Therapeutics from $26.00 to $28.00 and gave the company an “outperform” rating in a report on Thursday, November 14th. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Astria Therapeutics currently has an average rating of “Buy” and an average target price of $25.60.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.